Negative regulators of angiogenesis: important targets for treatment of exudative AMD.

Nickells Lab // Publications // Sheibani Lab // Aug 01 2017

PubMed ID: 28679845

Author(s): Farnoodian M, Wang S, Dietz J, Nickells RW, Sorenson CM, Sheibani N. Negative regulators of angiogenesis: important targets for treatment of exudative AMD. Clin Sci (Lond). 2017 Jul 5;131(15):1763-1780. doi: 10.1042/CS20170066. Print 2017 Aug 1. Review. PMID 28679845

Journal: Clinical Science (London, England : 1979), Volume 131, Issue 15, Aug 2017

Angiogenesis contributes to the pathogenesis of many diseases including exudative age-related macular degeneration (AMD). It is normally kept in check by a tightly balanced production of pro- and anti-angiogenic factors. The up-regulation of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), is intimately linked to the pathogenesis of exudative AMD, and its antagonism has been effectively targeted for treatment. However, very little is known about potential changes in expression of anti-angiogenic factors and the role they play in choroidal vascular homeostasis and neovascularization associated with AMD. Here, we will discuss the important role of thrombospondins and pigment epithelium-derived factor, two major endogenous inhibitors of angiogenesis, in retinal and choroidal vascular homeostasis and their potential alterations during AMD and choroidal neovascularization (CNV). We will review the cell autonomous function of these proteins in retinal and choroidal vascular cells. We will also discuss the potential targeting of these molecules and use of their mimetic peptides for therapeutic development for exudative AMD.

© 2017 The Author(s), published by Portland Press Limited on behalf of the Biochemical Society.